Synthesis of MeON-neoglycosides of DIGOXIGENIN (cas 1672-46-4) with 6-deoxy- and 2,6-dideoxy-d-glucose derivatives and their anticancer activity

Add time:09/24/2019    Source:sciencedirect.com

Cardiac glycosides show anticancer activities and their deoxy-sugar chains are vital for their anticancer effects. In order to study the structure-activity relationship (SAR) of cardiac glycosides toward cancers and get more potent anticancer agents, a series of MeON-neoglycosides of DIGOXIGENIN (cas 1672-46-4) was synthesized and evaluated. First, ten 6-deoxy- and 2,6-dideoxy-d-glucopyranosyl donors were synthesized starting from methyl α-d-glucopyranoside and 2-deoxy-d-glucose. Meanwhile, the digoxigenin was obtained by acidic hydrolysis of commercially available digoxin as glycosyl acceptor. Then, a 22-member MeON-neoglycoside library of digoxigenin was successfully synthesized by neoglycosylation method. Finally, the induction of Nur77 expression and its translocation from the nucleus to cytoplasm together with cytotoxicity of these MeON-neoglycosides were evaluated. The SAR analysis revealed that C3 glycosylation is required for their induction of Nur77 expression. Moreover, some MeON-neoglycosides (2b and 8b) could significant induce the expression of Nur77 and its translocation from the nucleus to cytoplasm. However, these compounds showed no inhibitory effects on the proliferation of cancer cells, suggesting that they may not induce apoptosis of NIH-H460 cancer cells and their underlying potential and application toward cancer cells deserves future study.

We also recommend Trading Suppliers and Manufacturers of DIGOXIGENIN (cas 1672-46-4). Pls Click Website Link as below: cas 1672-46-4 suppliers

Prev:Research paperSynthesis of C3-Neoglycosides of DIGOXIGENIN (cas 1672-46-4) and their anticancer activities
Next:The cardenolides strophanthidin, DIGOXIGENIN (cas 1672-46-4) and dihydroouabain act as activators of the human RORγ/RORγT receptors)